Technology evaluation: colostrinin, ReGen.

Curr Opin Mol Ther

King's College London, The Wolfson Centre for Age-Related Diseases, London, UK.

Published: February 2005

ReGen Therapeutics is developing Colostrinin, a polypeptide complex derived from ovine colostrums, for the potential treatment of Alzheimer's disease. The compound is currently undergoing phase II clinical trials.

Download full-text PDF

Source

Publication Analysis

Top Keywords

technology evaluation
4
evaluation colostrinin
4
colostrinin regen
4
regen regen
4
regen therapeutics
4
therapeutics developing
4
developing colostrinin
4
colostrinin polypeptide
4
polypeptide complex
4
complex derived
4

Similar Publications

Population-level Impact of HPV Vaccination on the Incidence of Genital Warts in Sweden.

J Infect Dis

January 2025

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels väg 12A, SE-17177 Stockholm, Sweden.

Background: Sweden introduced HPV vaccination in 2006, administered through opportunistic, subsidized, catch-up and school-based programs. Notably, genital warts (GW) are the first observable clinical outcome following infection by HPV-6/11, targeted by vaccination. We aim to gain knowledge of the incidence of GW in Sweden and evaluate its change throughout vaccination programs.

View Article and Find Full Text PDF

Background: Lifestyle interventions have been acknowledged as effective strategies for preventing type 2 diabetes mellitus (T2DM). However, the accessibility of conventional face-to-face interventions is often limited. Digital health intervention has been suggested as a potential solution to overcome the limitation.

View Article and Find Full Text PDF

Purpose: To explore the perceived utility and effect of simplified radiology reports on oncology patients' knowledge and feasibility of large language models (LLMs) to generate such reports.

Materials And Methods: This study was approved by the Institute Ethics Committee. In phase I, five state-of-the-art LLMs (Generative Pre-Trained Transformer-4o [GPT-4o], Google Gemini, Claude Opus, Llama-3.

View Article and Find Full Text PDF

Data collected from scholars across twenty-three countries over the past decade (2010-2019) reveals a 40% decrease in financial support for medicinal chemistry projects. The decline is especially notable among projects focused on small organic molecules. This drop in grants indicates a troubling trend that could jeopardize future drug development by undermining research in this crucial field.

View Article and Find Full Text PDF

The TOXIN knowledge graph: supporting animal-free risk assessment of cosmetics.

Database (Oxford)

January 2025

Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels 1090, Belgium.

The European Union's ban on animal testing for cosmetic products and their ingredients, combined with the lack of validated animal-free methods, poses challenges in evaluating their potential repeated-dose organ toxicity. To address this, innovative strategies like Next-Generation Risk Assessment (NGRA) are being explored, integrating historical animal data with new mechanistic insights from non-animal New Approach Methodologies (NAMs). This paper introduces the TOXIN knowledge graph (TOXIN KG), a tool designed to retrieve toxicological information on cosmetic ingredients, with a focus on liver-related data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!